Buy Daurismo at Insulinhub at a 30% discount from Europe.
Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Daurismo originating from Europe is manufactured at the following site(s):Pfizer Manufacturing Deutschland GmbH Betriebsstätte Freiburg Mooswaldallee 1 79090 Freiburg Germany
Information about Daurismo (Glasdegib)
Daurismo is the brand name for glasdegib, an oral medication that is used in the treatment of certain types of cancer. Glasdegib is a small molecule inhibitor of the Hedgehog signaling pathway, which is involved in regulating cell growth and development. By blocking this pathway, glasdegib helps to inhibit the growth of cancer cells and tumor progression.
Product Highlights
- Used in oncology for specific cancer treatments.
- Daurismo is primarily indicated for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are not candidates for intensive chemotherapy.
Key Ingredient
Key Benefits
- Specifically targets the Hedgehog signaling pathway, which plays a role in the growth and maintenance of cancer cells.
- Provides an option for patients with acute myeloid leukemia who are not eligible for intensive chemotherapy.
- Can help in achieving better clinical outcomes in combination with standard therapies for AML.
Direction of Use
- The usual dosage is 100 mg of glasdegib taken once daily.
- The tablets should be swallowed whole with water, and it is recommended to take them at the same time each day.
- Dosage adjustments may be necessary based on tolerance and side effects.
Safety Concerns
- Common side effects include nausea, diarrhea, fatigue, decreased appetite, and weight loss. More serious side effects can include anemia, neutropenia, and liver enzyme abnormalities.
- Glasdegib is classified as a Category D drug in pregnancy, meaning there is evidence of risk to the fetus. Effective contraception is required during treatment and for a period after completion of therapy.
Avoid Daurismo (Glasdegib) If
- Avoid use during pregnancy due to potential harm to the developing fetus. Women who are capable of becoming pregnant should employ effective methods of contraception.
- Avoid in patients with severe liver impairment, as glasdegib is metabolized by the liver and severe impairment may affect its clearance.
- Avoid if there is a known hypersensitivity to glasdegib or any of its components.
